We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows

By LabMedica International staff writers
Posted on 25 Mar 2025
Print article
Image: Interoperable AI-powered digital pathology workflows support confident cancer diagnosis (Photo courtesy of Royal Philips)
Image: Interoperable AI-powered digital pathology workflows support confident cancer diagnosis (Photo courtesy of Royal Philips)

Royal Philips (Amsterdam, The Netherlands) has expanded its partnership with Ibex Medical Analytics (Tel Aviv, Israel) and released the new Philips IntelliSite Pathology Solution (PIPS) to further accelerate the adoption of AI-enabled digital pathology to address the pressure pathologists face because of the global shortage of pathologists and the growing number of cancer patients. Following the start of the partnership in 2021, Philips and Ibex can offer even further interoperability of its solutions, aiming to enhance diagnostic workflows for clinicians and enabling better care for more people.

Ibex's AI and Philips’ digital pathology solution have shown to improve reporting efficiency and drive productivity gains of up to 37%. Through this partnership, pathology laboratories are able to utilize PIPS, which includes the full portfolio of scanners and Image Management System, and Ibex’s platform of AI-powered tools for prostate, breast and gastric cancer diagnostics. Expanding access and streamlining the use of AI-powered tools in digital pathology will further enhance the efficiency and effectiveness of pathology labs. Enabling AI directly in digital pathology workflows empowers clinicians to generate objective, reproducible results, increasing diagnostic confidence and enabling the productivity improvements needed to address the growing demand for pathology-based diagnostics. By further integrating Ibex's AI with PIPS, the solutions can offer optimized workflows, including help with case prioritization, AI-powered cancer detection and reporting, providing easier integration of productivity enhancing tools for more confident diagnosis, supporting better patient care.

Philips is also introducing Philips IntelliSite Pathology 6.0, including several new features and AI capabilities into the system. By providing advanced analysis and insights based on the context of the scanned images, pathology teams can access a seamless, AI-powered clinical workflow solution, from case management through to diagnosis and reporting. PIPS 6.0 features improved workflows and enhancements including full scan mode for the pathology SG scanner and contextual launch of AI [2] and counter marker tool in the image management system, as well as improved scalability. AI focused worklists show AI processing status at a case level and slides can automatically be shared with Ibex AI applications, for processing right after digitization. This new version of the Philips digital pathology solution offers optimized workflows, designed to enhance the efficiency and improved patient care. Based on Philips’ collaboration with Amazon Web Services, offerings for cloud archival services will allow pathology labs to efficiently and securely store, manage, and analyze growing volumes of digital pathology data.

“Pathology provides key information for a precise diagnosis. The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis,” said Sam Terese, President & CEO of Alverno Laboratories. “These integrated pathology solutions help us provide the highest possible quality result that any lab can deliver, getting answers back to our clinicians quickly and saving patients sleepless nights, even on complex cases.”

“The enhanced interoperability between Philips and Ibex platforms, which are now more seamlessly integrated into our diagnostic workflows, will accelerate the adoption of augmented pathology tools in which we strongly believe,” said Stéphane Rossat, Innovation & Scientific Director and Project Management at Medipath. “PIPS 6.0 promises to facilitate adoption by our physicians, thanks to its streamlined navigation and optimized workflows. We are eager to contribute to the evolution toward true digital "cockpits," which will become the reference interface for our pathologists.”

Related Links:
Royal Philips
Ibex Medical Analytics

Gold Member
Troponin T QC
Troponin T Quality Control
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Pathology

view channel
Image: Microscopic images showing healthy villi on the left and diseased villi on the right (Photo courtesy of Florian Jaeckle/University of Cambridge)

Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read more
Sekisui Diagnostics UK Ltd.